Geneva, Oct. 27 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134580) titled 'First-line treatment preferences for ALK-positive non-small cell lung cancer' on Oct. 16.

Study Type: Observational study

Study Design: Cross-sectional

Primary Sponsor: Henan Cancer Hospital

Condition: Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-10-19

Target Sample Size: Investigating group:150;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=347187

Disclaimer: Curated by HT Syndication....